Talphera (NASDAQ:TLPH) Upgraded at Maxim Group

Talphera (NASDAQ:TLPH) was upgraded by Maxim Group to a “strong-buy” rating in a report issued on Friday,Zacks.com reports.

Separately, HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Talphera in a research note on Friday, August 16th.

Talphera Stock Down 2.0 %

NASDAQ:TLPH opened at $0.89 on Friday. The firm has a market capitalization of $15.12 million, a P/E ratio of -1.39 and a beta of 0.31. The company has a fifty day moving average of $0.91 and a 200 day moving average of $0.94. Talphera has a 52 week low of $0.43 and a 52 week high of $1.61.

Talphera (NASDAQ:TLPH) last posted its earnings results on Wednesday, August 14th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07. As a group, analysts anticipate that Talphera will post -0.73 EPS for the current year.

Institutional Investors Weigh In On Talphera

A number of large investors have recently modified their holdings of TLPH. Nantahala Capital Management LLC bought a new position in Talphera in the second quarter worth about $1,773,000. Turtle Creek Wealth Advisors LLC purchased a new position in shares of Talphera in the 2nd quarter valued at approximately $64,000. Finally, Rosalind Advisors Inc. bought a new stake in shares of Talphera during the third quarter valued at approximately $650,000. Institutional investors own 37.67% of the company’s stock.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.